Zelira Therapeutics (ZLDAF)
OTHER OTC:ZLDAF
ZLDAF Stock Chart & Stats
$0.21
-$0.03(-7.39%)
At close: 4:00 PM EST
$0.21
-$0.03(-7.39%)
Day’s Range― - ―
52-Week Range$0.20 - $0.48
Previous CloseN/A
Volume342.00
Average Volume (3M)189.00
Market Cap
$4.26M
Enterprise Value$8.08M
Total Cash (Recent Filing)$5.66K
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding11,897,155
10 Day Avg. Volume15
30 Day Avg. Volume189
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market Cap1.90
Enterprise Value/Revenue12.34K
Enterprise Value/Gross Profit-10.07
Enterprise Value/Ebitda-1.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Cannabinoid R&D & CommercializationZelira's sustained focus on cannabinoid-based medicines and consumer health products represents a durable capability: it combines R&D and commercialization experience in a growing therapeutic niche, supporting long-term product pipelines and repeatable market entry strategies.
Multiple Monetization Channels (product + B2B Licensing)Having both direct commercial channels and B2B licensing/co-development options is a structural strength. It allows the company to pursue non-dilutive milestone/licensing revenue while scaling product sales, diversifying cash flow sources over the medium term.
Slight Improvement In Free Cash Flow GrowthEven within a negative cash flow profile, a measurable improvement in free cash flow growth signals early operational progress or cost control. If sustained, this can lengthen runway, reduce near-term financing pressure, and support incremental investment in core programs.
Bears Say
Severe Revenue CollapseA nearly complete loss of top-line revenue is a fundamental structural weakness. It erodes margins, limits reinvestment in R&D and commercialization, reduces bargaining power with partners, and raises the likelihood of dilution or asset sales to sustain operations.
Negative Shareholders' EquityNegative equity indicates balance-sheet instability and weak capital structure. This materially constrains access to traditional financing, increases cost of capital, and can obligate management to pursue corrective actions (capital raises, restructuring) that dilute existing holders.
Persistent Negative Margins And Cash FlowConsistently negative gross, EBIT and net margins alongside ongoing negative operating cash flow reflect a structural inability to generate profit from core activities. Absent durable margin recovery, the company will struggle to self-fund R&D, commercialization, or meaningful growth initiatives.
Zelira Therapeutics News
ZLDAF FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest stock price was $0.20 and its highest was $0.48 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is $4.26M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 92 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in ZLDAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Technical Analysis
Actinogen Medical
―
Tryptamine Therapeutics
―
Paradigm Biopharmaceuticals
―
Island Pharmaceuticals Ltd
―
Botanix Pharmaceuticals Limited
―